A patient-oriented risk–benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States
Article first published online: 15 OCT 2012
© 2012 American Association of Blood Banks
Volume 53, Issue 7, pages 1603–1618, July 2013
How to Cite
Kleinman, S., Reed, W. and Stassinopoulos, A. (2013), A patient-oriented risk–benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion, 53: 1603–1618. doi: 10.1111/j.1537-2995.2012.03928.x
- Issue published online: 11 JUL 2013
- Article first published online: 15 OCT 2012
- Manuscript Accepted: 25 AUG 2012
- Manuscript Revised: 24 AUG 2012
- Manuscript Received: 2 JUL 2012
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.